research and development

Domain name registry giant expands trademark protection offering

Donuts has grown significantly in recent months with nearly 300 TLDs now under management. Its new Domains Protected Marks List (DPML) creates an excellent opportunity for IP owners to protect their brands online by taking advantage of Donuts’ expanded offering. In recent years, we have observed increased acquisitive activity in the ever-changing domain name industry, […]

Women in Leadership and COVID-19: Spotlight on Sheila Borgman

We’re proud of the powerful roles that women at Clarivate have played in addressing COVID-19. In this continuing series, we share their stories. More than half of the colleagues in the science organization at Clarivate are women. Their achievements are invaluable to our contributions to innovation and customer success, as evidenced in the roles women […]

Innovative cardiovascular treatments: Top pharmacotherapy breakthroughs at AHA21

Clarivate experts share takeaways from the 2021 American Heart Association Scientific Sessions (AHA21), with insights on how findings may impact patient care. As part of our Drugs to Watch™ series, which reviews therapies expected to have significant impact on healthcare markets, Clarivate experts have selected their top picks from the AHA21 Scientific Sessions. This completely […]

How the pandemic shifted Roche’s priorities and R&D investments [PODCAST]

In this episode of Conversations in Healthcare, Richard Erwin discusses how Roche Products Limited (UK) has evolved their strategy during the pandemic.     In the past two years months, the healthcare industry demonstrated how it can mobilize its resources to tackle what has been one of the greatest healthcare challenges in history. During One […]

Annual G20 Scorecard: The link between COVID-19 response and research subject diversity

Our latest Global Research Report from the Institute for Scientific Information examines G20 member countries’ research performance and includes a special analysis of their COVID-19 research Each year we report our Annual G20 Scorecard as a prelude to the G20 Summit – a two-day gathering of the world’s major economies, set this year in Rome, […]

COVID-19: Fighting a global pandemic with innovation

In this episode of Ideas to Innovation, Clarivate life sciences and healthcare experts reflect on partnering with pharma to combat the pandemic. Listen now.   COVID-19 has presented an enormous global challenge, requiring an unprecedented level of engagement by stakeholders across pharma, research and policy. While SARS-CoV-2 emerged as a novel virus to which humans […]

Top oncology breakthroughs shared at ESMO 2021

Clarivate oncology experts share major takeaways from ESMO and their expected impact on the treatment landscape and patients. As part of our Drugs to Watch™ series, which reviews therapies expected to have significant impact on healthcare markets, Clarivate oncology experts sifted through the more than 2,800 abstracts that were accepted for presentation at the ESMO […]

Best practices for university-healthcare partnerships: Lessons from Oxford

In this episode of Conversations in Healthcare, Mike Ward speaks with Dr. Phil Clare, Deputy Director, Research Services, Knowledge Exchange and Engagement at the University of Oxford, about the process of translating academic research into new healthcare products and services.     Mike Ward: A key component of that ecosystem is the fundamental research that’s […]

Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo

Bristol’s Relatlimab/Opdivo (anti-LAG-3/PD-1) therapy is poised to make inroads into its own Opdivo/Yervoy (PD-1/CTLA-4) inhibitor combination share for malignant melanoma. As part of our Drugs to Watch™ series, Clarivate oncology experts Liseth Parra and Rachel Webster review new data shared at ASCO 2021, and implications for patients and life sciences companies.   Compelling Phase III […]